BioXcel Therapeutics Announces Proposed Public Offering
February 08 2024 - 4:01PM
BioXcel Therapeutics, Inc. (the “Company”) (Nasdaq: BTAI), a
biopharmaceutical company utilizing artificial intelligence
approaches to develop transformative medicines in neuroscience and
immuno-oncology, today announced that it has commenced an
underwritten public offering of $60.0 million of shares of its
common stock or, in lieu of common stock to certain investors that
so choose, pre-funded warrants to purchase shares of its common
stock. In addition, the Company expects to grant the underwriters a
30-day option to purchase up to $9.0 million of additional shares
of common stock at the public offering price, less the underwriting
discounts and commissions.
BofA Securities and Truist Securities are acting as joint
book-running managers for the proposed public offering. The
proposed public offering is subject to market and other conditions,
and there can be no assurance as to whether or when the offering
may be completed, or as to the actual size or terms of the
offering. All of the securities to be sold in the offering are
being sold by the Company.
The Company intends to use the net proceeds of this offering to
fund ongoing and planned clinical trials, commercialization and
general corporate purposes.
The securities are being offered pursuant to a shelf
registration statement on Form S-3 that was previously filed with
the Securities and Exchange Commission (the “SEC”) on November 2,
2023 and which became effective on November 13, 2023. This offering
is being made only by means of a written prospectus and prospectus
supplement that form a part of the registration statement. A
preliminary prospectus supplement relating to and describing the
terms of the offering will be filed with the SEC and will be
available on the SEC’s website at www.sec.gov. The final terms of
the offering will be disclosed in a final prospectus supplement to
be filed with the SEC. When available, copies of the preliminary
prospectus supplement and the accompanying prospectus relating to
the offering may also be obtained by contacting: BofA Securities,
Attention: Prospectus Department, NC1-022-02-25, 201 North Tryon,
Charlotte, NC 28255-0001, or by email at
dg.prospectus_requests@bofa.com; Truist Securities, Inc.,
Attention: Prospectus Department, 3333 Peachtree Road NE, 9th
floor, Atlanta, GA 30326, by telephone at (800) 685-4786, or by
email at TruistSecurities.prospectus@Truist.com.
This press release does not constitute an offer to sell or the
solicitation of an offer to buy the securities, nor shall there be
any sale of the securities in any jurisdiction in which such offer,
solicitation or sale would be unlawful prior to the registration or
qualification under the securities laws of such jurisdiction.
Forward-Looking StatementsThis press release
includes “forward-looking statements” within the meaning of the
Private Securities Litigation Reform Act of 1995. We intend such
forward-looking statements to be covered by the safe harbor
provisions for forward-looking statements contained in Section 27A
of the Securities Act of 1933, as amended (the “Securities Act”)
and Section 21E of the Securities Exchange Act of 1934, as amended
(the “Exchange Act”). All statements contained in this press
release other than statements of historical fact should be
considered forward-looking statements, including, without
limitation, those regarding the completion and size of the proposed
public offering and the Company’s expectation with respect to
granting a 30-day option to purchase additional shares of common
stock at the public offering price, as well as the risks and
uncertainties in the Company’s business, including those risks
discussed in the “Risk Factors” section in the preliminary
prospectus supplement relating to the offering. When used herein,
words including “anticipate,” “believe,” “can,” “continue,”
“could,” “designed,” “estimate,” “expect,” “forecast,” “goal,”
“intend,” “may,” “might,” “plan,” “possible,” “potential,”
“predict,” “project,” “should,” “target,” “will,” “would” and
similar expressions are intended to identify forward-looking
statements, though not all forward-looking statements use these
words or expressions. In addition, any statements or information
that refer to expectations, beliefs, plans, projections,
objectives, performance or other characterizations of future events
or circumstances, including any underlying assumptions, are
forward-looking. All forward-looking statements are based upon the
Company’s current expectations and various assumptions. The Company
believes there is a reasonable basis for its expectations and
beliefs, but they are inherently uncertain. The Company may not
realize its expectations, and its beliefs may not prove correct.
Actual results could differ materially from those described or
implied by such forward-looking statements as a result of various
important factors, including, without limitation, the important
factors discussed under the caption “Risk Factors” in its Quarterly
Report on Form 10-Q for the quarterly period ended September 30,
2023, as such factors may be updated from time to time in its other
filings with the SEC, which are accessible on the SEC’s website at
www.sec.gov. These and other important factors could cause actual
results to differ materially from those indicated by the
forward-looking statements made in this press release. Any such
forward-looking statements represent management’s estimates as of
the date of this press release. While the Company may elect to
update such forward-looking statements at some point in the future,
except as required by law, it disclaims any obligation to do so,
even if subsequent events cause our views to change. These
forward-looking statements should not be relied upon as
representing the Company’s views as of any date subsequent to the
date of this press release.
Contact Information
Corporate
BioXcel TherapeuticsErik
Kopp1.203.494.7062ekopp@bioxceltherapeutics.com
Investor Relations
BioXcel TherapeuticsBrennan
Doyle1.475.355.8462bdoyle@bioxceltherapeutics.com
Media
Russo PartnersDavid
SchullT: 858-717-2310David.Schull@russopartnersllc.comScott
StachowiakT: 646-942-5630Scott.Stachowiak@russopartnersllc.com
BT BIOXCEL THERAPEUTICS is a registered trademark of BioXcel
Therapeutics, Inc. All other trademarks are the properties of their
respective owners. Copyright © 2024, BioXcel Therapeutics, Inc. All
rights reserved.
BioXcel Therapeutics (NASDAQ:BTAI)
Historical Stock Chart
From Mar 2024 to Apr 2024
BioXcel Therapeutics (NASDAQ:BTAI)
Historical Stock Chart
From Apr 2023 to Apr 2024